Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar (2025-10-30)
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.